These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 35849517)

  • 1. Monoclonal antibodies for prophylaxis and treatment of respiratory viral infections.
    Boonyaratanakornkit J; Boeckh M; Waghmare A
    Curr Opin Infect Dis; 2022 Aug; 35(4):280-287. PubMed ID: 35849517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies to combat viral infections: development strategies and progress.
    Pantaleo G; Correia B; Fenwick C; Joo VS; Perez L
    Nat Rev Drug Discov; 2022 Sep; 21(9):676-696. PubMed ID: 35725925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: an update from the World Association of Infectious Diseases and Immunological Disorders and the Italian Society of Antinfective Therapy.
    Esposito S; Amirthalingam G; Bassetti M; Blasi F; De Rosa FG; Halasa NB; Hung I; Osterhaus A; Tan T; Torres JP; Vena A; Principi N
    Front Immunol; 2023; 14():1162342. PubMed ID: 37256125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
    Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
    mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.
    Vellas C; Del Bello A; Debard A; Steinmeyer Z; Tribaudeau L; Ranger N; Jeanne N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
    Clin Microbiol Infect; 2022 Jan; 28(1):139.e5-139.e8. PubMed ID: 34537363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the Combined Public Health Impact of Pharmaceutical Interventions on Pandemic Transmission and Mortality: An Example in SARS CoV-2.
    Kamal MA; Kuznik A; Qi L; Więcek W; Hussein M; Hassan HE; Patel K; Obadia T; Toroghi MK; Conrado DJ; Al-Huniti N; Casciano R; O'Brien MP; Barnabas RV; Cohen MS; Smith PF
    Clin Pharmacol Ther; 2022 Dec; 112(6):1224-1235. PubMed ID: 35984050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
    Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
    J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic on the Epidemiology of Pediatric Respiratory Syncytial Virus Infection.
    Odumade OA; van Haren SD; Angelidou A
    Clin Infect Dis; 2022 Aug; 75(Suppl 1):S130-S135. PubMed ID: 35579506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal Antibodies and their Target Specificity Against SARS-CoV-2 Infections: Perspectives and Challenges.
    Bakkari MA; Moni SS; Sultan MH; Madkhali OA
    Recent Pat Biotechnol; 2022; 16(1):64-78. PubMed ID: 34994337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization.
    Huang DT; McCreary EK; Bariola JR; Wadas RJ; Kip KE; Marroquin OC; Koscumb S; Collins K; Shovel JA; Schmidhofer M; Wisniewski MK; Sullivan C; Yealy DM; Axe M; Nace DA; Haidar G; Khadem T; Linstrum K; Snyder GM; Seymour CW; Montgomery SK; McVerry BJ; Berry L; Berry S; Meyers R; Weissman A; Peck-Palmer OM; Wells A; Bart R; Albin DL; Minnier T; Angus DC
    Trials; 2021 May; 22(1):363. PubMed ID: 34034784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.
    ter Meulen J; van den Brink EN; Poon LL; Marissen WE; Leung CS; Cox F; Cheung CY; Bakker AQ; Bogaards JA; van Deventer E; Preiser W; Doerr HW; Chow VT; de Kruif J; Peiris JS; Goudsmit J
    PLoS Med; 2006 Jul; 3(7):e237. PubMed ID: 16796401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection.
    Bruzzesi E; Ranzenigo M; Castagna A; Spagnuolo V
    New Microbiol; 2021 Jul; 44(3):135-144. PubMed ID: 34783348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.
    Boyoglu-Barnum S; Chirkova T; Todd SO; Barnum TR; Gaston KA; Jorquera P; Haynes LM; Tripp RA; Moore ML; Anderson LJ
    J Virol; 2014 Sep; 88(18):10569-83. PubMed ID: 24990999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
    Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W
    Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice.
    Caidi H; Harcourt JL; Tripp RA; Anderson LJ; Haynes LM
    PLoS One; 2012; 7(12):e51485. PubMed ID: 23300550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies constructed from COVID-19 convalescent memory B cells exhibit potent binding activity to MERS-CoV spike S2 subunit and other human coronaviruses.
    Peng Y; Liu Y; Hu Y; Chang F; Wu Q; Yang J; Chen J; Teng S; Zhang J; He R; Wei Y; Bostina M; Luo T; Liu W; Qu X; Li YP
    Front Immunol; 2022; 13():1056272. PubMed ID: 36618428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.
    Zheng Z; Monteil VM; Maurer-Stroh S; Yew CW; Leong C; Mohd-Ismail NK; Cheyyatraivendran Arularasu S; Chow VTK; Lin RTP; Mirazimi A; Hong W; Tan YJ
    Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA
    J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
    Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
    Front Immunol; 2021; 12():790469. PubMed ID: 34956222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.